TABLE 3.

Outcome Studies on Bridge to Recovery

Study year	Design	N	Adjuvant antiremodeling drug protocol	Protocol for monitoring cardiac function	Unloading duration (m)	Recovery overall [N (%)]	Recovery nonischemic [N (%)]	HF recurrence/follow-up
US multicenter, 2007	P	67	Not standardized	YES	4.5	6(9)	5(13.5)	Freedom from death or Tx 100%/6 months
Berlin Group, 2008, 2010 2012 2010 (18, 18, 19, 19)	R	188	Not standardized	YES	4.3	35 (18.6)	35 (18.6)	Freedom from recurrent HF 74 and 66%/3 and 5 years, respectively
Harefield Group, 2006	P	15	Yes	YES	10.6	11 (73)	11 (73)	Freedom from recurrent HF 100 and 89%/1 and 4 years, respectively
Harefield Group, 2011	P	20	Yes	YES	9.5	12 (60)	12 (60)	Freedom from recurrent HF 83.3%/3 years
University of Athens-Harefield Group, 2007	P	8	Yes	YES	6–10	4a(50)	4a(50)	Freedom from recurrent HF 100%/2 years
Gothenburg Group, 2006	P	18	Not standardized	YES	6.7	3 (17)	3 (20)	Freedom from recurrent HF or Tx 33%/8 years
Pittsburgh Group, 2003	R	18	Not standardized	YES	7.8	6 (33)	5 (38)	Freedom from recurrent HF 67%/1 year
Osaka Group, 2005	R	11	Not standardized	N/A	15.1	5 (45)	5 (45)	Freedom from recurrent HF 100%/8 to 29 months
Pittsburgh Group, 2010	R	102	N/A	N/A	4.9	14 (13.7)	14 (13.7)	Freedom from recurrent HF or death 71.4%/5 years
Multicenter, 2001	R	271	N/A	N/A	1.9	22(8.1)	22(8.1)	Freedom from recurrent HF or death 77%/3.2 years
Columbia Group, 1998	R	111	N/A	N/A	6.2	5(4.5)	4 (8)	Freedom from recurrent HF or death 20%/15 months

HF, heart failure; m, months; N, number; N/A, not applicable; P, prospective studies; R, retrospective studies; Tx, transplant.

^aA fifth patient fulfilled recovery criteria (5/8, 62.5%) but died of stroke just before LVAD explantation.

Full references for the above studies are provided in the online data supplement and in reference {18442)

Modified from reference {18442}